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Abstract
Diagnostic imaging (DI) is the fastest growing sector in med-
ical expenditures and takes a central role in medical decision-
making. The increasing number of various and new imaging
technologies induces a growing demand for cost-effectiveness
analysis (CEA) in imaging technology assessment. In this
article we provide a comprehensive framework of direct and
indirect effects that should be considered for CEA in DI, suit-
able for all imaging modalities. We describe and explain the
methodology of decision analytic modelling in six steps
aiming to transfer theory of CEA to clinical research by dem-
onstrating key principles of CEA in a practical approach. We
thereby provide radiologists with an introduction to the tools
necessary to perform and interpret CEA as part of their re-
search and clinical practice.
Key Points
• DI influences medical decision making, affecting both costs
and health outcome.
• This article provides a comprehensive framework for CEA in
DI.
• A six-step methodology for conducting and interpreting cost-
effectiveness modelling is proposed.
Keywords Cost Effectiveness . DecisionModelling .
Diagnostic Imaging . Economics . TechnologyAssessment
Introduction
Increasing scrutiny of healthcare costs leads to a demand for
proof of value for all medical expenditures. Cost-effectiveness
analyses (CEA) intend to provide additional information
about the possibilities of maximizing health effects, taking
into account limited health care resources [1]. CEA have al-
ready become common practice in the evaluation of disease
treatment strategies and diagnostic screening programs [2].
Diagnostic imaging (DI) is currently the fastest growing cate-
gory in medical expenditure [3, 4]. Over the last years, an
increasing number of CEA of DI technologies have been pub-
lished [5–12], though broad application has yet to happen. The
distinct central role diagnostic imaging plays in medical deci-
sion-making, as well as the continued emergence of new and
varied imaging technologies, increases the importance of cost-
effectiveness evaluation in imaging technology assessment.
Several articles provide an overview on the theory of CEA
in DI [13–15]. Although they contain excellent technical
background, radiologists and other DI professionals still might
feel insecure in performing and interpreting CEA, as econom-
ic evaluation is not part of medical training. Even for those
doctors who received additional training, performing CEA
analyses in DI is challenging due to missing standardized
methodologies. Furthermore, the effects both on costs and
health outcome largely depend on the treatment strategy deci-
sions that are made based on the imaging results themselves.
Consideration of these remote indirect effects requires more
complex methodologies for CEA in DI compared to CEA in
therapeutic services [16]. Synthesis of available evidence in-
corporated in decision analytic modelling forms the link
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between a diagnostic test and its effects in terms of costs and
health outcome. A comprehensive practical guide to the use of
decision modelling techniques can be found in the book of
Briggs et al. [17]. The aim of this article is to provide an
introduction to the tools necessary to perform and interpret
CEA. We thereby transfer the theory of evidence synthesis
and decision analytic modelling to practical clinical research
by demonstrating key principles and steps of CEA in diagnos-
tic imaging.
Rationale of cost-effectiveness analysis in diagnostic
imaging
A cost-effectiveness analysis is the comparative analysis of
alternative courses of action in terms of both their costs and
consequences. In imaging, these alternative courses of action
can be utilization of different imaging techniques, or, more
generally, imaging versus no imaging. The rationale of CEA
in DI is that the choice of DI test influences both costs as
well as effectiveness of disease management. In a concep-
tual framework developed by Fineberg et al. [18] and mod-
ified by others [19], effectiveness of a diagnostic test is
expressed on subsequent hierarchical levels: technical per-
formance, diagnostic accuracy, diagnostic impact, thera-
peutic impact and health outcome. Effectiveness in terms
of patients’ health outcome is indirectly influenced by the
diagnostic test due to medical care decisions based on im-
aging. The health outcome can also directly be affected by
the imaging test itself. Health effects can be physical, for
example because of altered treatment, and psychological,
for example because of receiving a diagnosis. Direct and
indirect health effects can be measured in utility scores,
from which Quality Adjusted Life Years (QALYs) can be
derived, combining survival and quality of life. Both phys-
ical and psychological health conditions are incorporated
in a QALY. Looking at costs, these are directly affected by
the costs of the diagnostic test itself as well as indirectly
influenced by costs of treatment chosen based on imaging
and resulting costs of patients’ health outcome. Figure 1
illustrates the concept of these direct and indirect effects
used in CEA in DI.
When assessing the cost-effectiveness of DI, the initial
question is whether adding an imaging test in a medical path-
way does improve medical decision-making. Taking a hypo-
thetical 100 % accuracy for a test would be used to assess
changes in outcome by adding this particular test to the med-
ical pathway. Only if the perfectly accurate test provides
added value, it is reasonable to continue the analysis with
the actual sensitivity and specificity of the test [20]. However,
in many clinical situations imaging is already an existing stan-
dard part of the particular disease management. CEA is, there-
fore, used to compare potential new imaging technologies or
imaging strategies to each other as well as to the current ref-
erence standard. We will focus on this second model through-
out the article.
Decision-analytic modelling
While studies are being performed to inform decision makers
about optimal DI tests, these studies often focus on the accu-
racy and short-term effects of the imaging test. However, for
decision making it is also important to know how well a test
can help to improve health outcome (e.g., survival and/or
quality of life) [16, 21]. In addition, the societal impact may
be relevant, including the cost-effectiveness or value for the
money needed for a diagnostic test. It is possible to undertake
trials that include such long-term consequences but these trials
are often costly and practically challenging, due to the remote-
ness of the effects, requiring long follow-up periods and large
sample sizes. Moreover, withholding a non-invasive imaging
test that might provide useful diagnostic information may cre-
ate ethical dilemmas.
Given these limitations, decision-analytic modelling is of-
ten used to synthesize data from trials with other available
evidence [13]. Hence, the characteristics of a diagnostic test
(e.g., sensitivity and specificity) can be linked with long-term
patient outcomes. The results of these models tend to better fit
the needs of decision makers.
The development and analysis of a decision-analytic model
proceeds in a stepwise fashion. Comprehensive guidelines
were recently published [22]. We present a six-step method-
ology for CEA in DI, including: (1) Defining the decision
problem, (2) Choosing, and further developing the decision
model, (3) Selecting input parameters, (4) Analysis and uncer-
tainty analysis, (5) Interpretation of results , and (6) Transfer-
ability and validation.
Defining the decision problem
A research question is developed with a clear statement of the
imaging decision problem,modelling objectives and the scope
of the model. Factors to consider are the decision maker (e.g.
government or medical doctor), the perspective (e.g., societal
perspective if government is the decision maker or health care
perspective for medical doctor), comparators (which imaging
strategies should be compared in the analysis), outcomes of
the model (e.g., which health consequences are relevant), and
target population (for which patients is the decision relevant).
It is important to note that this step should be driven by the
decision problem and research question, and not by data avail-
ability [23]. We will illustrate how a decision model can be
used for medical imaging by addressing the question whether
18FDG-Positron-Emission-Tomography computed
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tomography (18FDG-PET-CT) is cost-effective compared to
CT or conventional chest X-ray in the follow-up of patients
with non-small cell lung cancer (NSCLC) after radical radio-
therapy [6]. The decision maker in this example is the medical
doctor with a clear health perspective, with a choice of three
imaging techniques to use in the follow-up of patients with
NSCLC after potentially curative treatment. The expected
costs and effects were calculated over a period of five years.
Outcome is defined as patients’ health state, which is mea-
sured in QALYs.
Developing the decision model
Following the definition of the decision problem, the second
step consists of developing the decision model by choosing an
appropriate model structure. In medical imaging, decision
trees and Markov models are most commonly used [24].
The decision tree
To visualize and calculate the effects of imaging on costs and
health outcome in a static situation and short time frame, a
flow model in the form of a decision tree can be used and
easily made in Excel (Microsoft, Redmond, WA) or other
spreadsheet application software. A hypothetical cohort of
patients passes through the model and is divided over the
different pathways in the decision tree, according to the
assigned probabilities. A decision tree starts with a decision
node, after which the alternative strategies are depicted. In
each strategy, patients in the model do or do not have the
disease or condition of interest and undergo an imaging test
for diagnostic workup. Medical care decisions are based on
the imaging results and determine whether patients undergo
further imaging or other diagnostic tests and possible therapy.
At the end of the decision tree, the cohort is divided into
different possible health outcomes due to characteristics of
diagnostic imaging and choice of therapy. These health out-
comes can be assigned QALYs and are based on whether
patients are alive and, when they are alive, whether they
experience problems that may impact quality of life. Costs
are the sum of the costs that occur in the pathways, such as
costs for the imaging tests and eventual therapy, and health
outcome related costs. Two or more diagnostic tests can be
compared with each other: using the sensitivity and specificity
of the different imaging modalities, the probabilities to be
accurately diagnosed with corresponding optimal treatment
can be assessed in the decision tree model. A schematic deci-
sion tree for the example of 18FDG-PET-CT versus CT versus
chest X-ray in the follow-up of curatively treated NSCLC is
shown in Fig. 2, which is a simplified version of a decision
tree used in a recently published study [6].
The Markov model
In non-static situations, such as in chronic diseases or malig-
nancies, health states of the patients may alter depending on
imaging and treatment options. In such situations, a Markov
model can be used to reflect alterations in health states during
the period of CEA. In a Markovmodel, the clinical situation is
described in terms of the conditions that patients can be in
(‘health states’), how they can move in such states (‘transi-
tions’), and how likely such moves are (‘transition probabili-
ties’) [25]. The time frame of the analysis can be chosen as
suitable for the underlying medical question with respect to
the available literature. For CEA of screening imaging tests
and follow-up imaging in cancer, a long frame over several
years or lifetime may be adequate. For example, in a Markov
model used for the decision problem on optimal follow-up
imaging after treated NSCLC, patients can be in the health
states Bno evidence of disease^, Bprogressive disease^ or
Bdead^ (Fig. 3). Progressive disease can be detected (i.e., the
true positive test results) or not (the false negative test results).
No evidence of disease represents the paths in the decision tree
Fig. 1 Comprehensive
framework of cost-effectiveness
analysis in diagnostic imaging
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with true negatives and the false positives test results. At each
time point of follow-up imaging, patients stay in the state they
are, or move to different states, e.g., from no evidence of
disease to progressive disease (and vice versa) or from no
evidence of disease or progressive disease to dead. Please note
that in this example, theMarkovmodel directly follows on the
health outcomes in the decision tree. It is common practice in
imaging studies to combine a decision tree for the short-term
diagnostic accuracy and treatment decision with a Markov
model for the longer-term consequences of the disease.
Model input parameters
To predict costs and health outcome as effects of DI, both the
direct and indirect effects of the imaging test itself on health
outcome and costs should be considered as model input pa-
rameters (Fig. 1).
Direct effects
Direct effects are those that apply for all patients undergoing
the diagnostic test regardless of the outcome of the test. Direct
effects of imaging modalities on health vary, depending on the
modality used, from negligible in, e.g. ultrasound, to consid-
erable in invasive techniques like catheter angiography. The
Bconsiderable^ effects are mainly a consequence of the risk of
complications inherent to these invasive techniques. The use
of contrast agents in diagnostic imaging carries the risk of
adverse reactions and nephrotoxicity [26–29]. The effects of
these sequelae on health status depend on the chemical prop-
erties of the contrast agent used and the way it is administered
(oral, intravenous, intra-arterial, intrathecal). Radiation expo-
sure from diagnostic tests using X-Rays has a small but not
negligible effect on health status especially in models address-
ing a large patient population. The risk of inducing cell muta-
tions is present in all diagnostic modalities using X-Rays and
increases with radiation dose and exposure times. Data on
these risks are provided in the Biological Effects of Ionizing
Radiation (BEIR) reports [30]. Besides these stochastic effects
of radiation exposure deterministic effects, or tissue reactions,
can occur at high dosage or long exposure times. These effects
occur above a certain threshold and should, therefore, only be
considered if there is a possibility that this threshold will be
reached. Direct psychological health effects of imaging should
be considered in CEA ofDI if relevant, for example if imaging
is very burdensome [31, 32]. These effects consist of potential
short-term psychological effects of the imaging test itself.
Direct costs of diagnostic testing include depreciation of
the hardware, cost of personnel and materials (e.g., contrast
agents). To be considered in the determination of these direct
costs are influencing factors like imaging time and mode of
utilization of the equipment (24/7 versus office hours) since
both define the patient throughput for the imaging equipment.
The latter form of direct costs rise especially when using ex-
pensive hardware and long examinations, such as MRI and
PET. Besides the aforementioned types, additional costs
caused by the above described adverse events and complica-
tions need to be included based on their prevalence. These
costs comprise additional hospitalization and treatment costs.
Ultimately societal costs of radiation-induced malignancies
can be transferred to additional costs of those tests for which
Fig. 2 Schematic example of a
decision tree model
Fig. 3 Schematic example of a Markov model
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this is applicable. Ideally real costs are used in a CEA, and
tariffs or reimbursement fees are used only if they accurately
represent the real costs.
Indirect effects
Indirect effects of a diagnostic test depend on the conse-
quences of the test result. Both health status and costs related
to this health status are characteristics of the patient and diag-
nostic tests do not directly change these parameters. Diagnos-
tic tests guide the management of patients. Assuming optimal
circumstantial factors, a Bperfect^ diagnostic test will theoret-
ically result in the optimal management. One may assume that
the optimal management leads to the best health status (though
not necessarily to lowest costs). BImperfect^ diagnostic tests
will in some cases lead to suboptimal management. The effect
of diagnostic tests on outcome parameters lies, therefore, only
in the imperfectness of the test, usually presented as sensitivity
and specificity, or positive and negative predictive values.
Indirect psychological effects are gaining more attention and
consist of the positive or negative psychological effects of the
diagnostic information of the test result on a patient’s view on
his or her health [32–34].
Outcome parameters for health status are generally repre-
sented as quality-adjusted life years (QALYs), although other
outcome parameters might be used for specific study objec-
tives (e.g., life-years saved). QALYs are derived from the
general life expectancy estimates of the target population
and disutilities (i.e., reduction in quality of life) related to the
disease of interest, the treatment, and the diagnostic test. The
use of QALYs allows for the relative importance of false pos-
itive or negative results of a diagnostic test (reflected in sen-
sitivity and specificity) to be weighed. Costs are calculated
from the allocated treatment, medication, hospitalization, etc.
Furthermore, costs can be transferred from known societal
costs of specific health conditions that might apply. Table 1
provides a schematic overview of model input parameters for
the example of different follow-up imaging strategies in cura-
tively treated NSCLC [6].
Analysis of values and uncertainty
Cost-effectiveness modelling serves two purposes. First,
it serves as an estimation of expected costs and outcomes
for medical decision-making. Secondly, it assesses the
uncertainties around these estimates and its range of
validity [36].
The expected costs and outcomes can be obtained by mul-
tiplying the probabilities with their relevant costs and health
outcomes. This results in average expected values per patient,
for costs as well as health outcome. Specific software (e.g.,
TreeAgePro, TreeAge Software, Williamstown, MA, U.S.)
can be used for this purpose, but Markov models and decision
trees are also often analyzed using standard PC software
(Microsoft Excel). The quality of estimates derived from the
model directly depends on the quality of the input parameters.
In general, the input parameters are desired to be as evidence-
based as possible. However, model input parameters are
surrounded by uncertainties. Parameter uncertainty reflects
the uncertainty of the model input parameters because we do
not know the precise values. This can be a result of multiple
and conflicting or low quality studies, or merely from varia-
tion in the data as reflected in standard deviations surrounding
a mean estimate. Parameter uncertainty can be addressed by a
deterministic or probabilistic sensitivity analysis [36]. In a
deterministic sensitivity analysis the mean values of the input
parameters are altered to assess impact on total cost and out-
come of the model. Even in the case when input parameters of
the model might not be available, hypothetical values and
borders can be set in the model to determine hypothetical
estimates.
Alternatively, parameter uncertainty can be addressed by
means of a probabilistic sensitivity analysis. Each uncertain
model input parameter is assigned a distribution, based on
the mean and standard deviation/error as found in the liter-
ature. Examples of distributions surrounding the input pa-
rameters can be found in Table 1. In the probabilistic sensi-
tivity analysis, different samples are taken from these distri-
butions. For each sample, the hypothetical cohort runs
through the model based on these sampled probabilities,
and costs and outcome are derived. This results in a range
of estimates of costs and outcome, representing the uncer-
tainty in the result of the cost-effectiveness estimation. This
range in outcome is usually expressed as 95 % Confidence
Intervals (CI), based on the probabilistic analysis. In our
example, the expected costs per patient are € 15,266
(95 % CI € 14,072–16,440) and expected QALYs 1.30
(95 % CI 1.00–1.61), if all patients were to receive PET-
CT at three months follow-up.
Interpretation of the results
When interpreting the results of the model, total estimated
costs of diagnostic test, treatments and health state are com-
pared to estimate health outcome over the chosen period of
time. Figure 4 graphically illustrates the costs versus effective-
ness comparison. The imaging strategy that yields the highest
number of QALYs is considered most effective. If a strategy is
less costly and more effective, it is cost-effective and superior
to the alternative strategy (Fig. 4d). If a strategy is more costly
and less effective than its alternative, it is dominated by the
alternative (Fig. 4a).
A decision-analytic perspective implies that for an imaging
strategy to be adopted, it has to be cost-effective compared to
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its next best alternative [37]. In case the strategy is more costly
and more effective, or less costly and less effective than the
alternative (Fig. 4b,c), incremental cost-effectiveness ratios
(ICERs) need to be calculated by dividing the incremental
costs by the incremental QALYs. The decision whether the
strategy is deemed cost-effective then depends on how much
society is willing to pay for a QALY gained or lost. In the
Netherlands, for example, the informal societal willingness
to pay (WTP) threshold level is € 80,000 [38]. If in quadrant
b the ICER is lower than this level, the strategy is cost-
effective compared to the alternative (Fig. 4b). In quadrant
c, the ICER needs to be higher than the WTP in order to be
cost-effective. To illustrate the results of the probabilistic
sensitivity analysis, cost-effectiveness acceptability curves
(CEACs) can be calculated [39]. CEACs are shown in
Fig. 5 demonstrating the probability that a strategy is cost-
effective, given different values of willingness to pay for a
QALY. This figure shows that if societal WTP for a QALY is
low, conventional follow-up is certainly the most cost-
effective strategy. If the willingness to pay increases, the
probability that this is true decreases. At a willingness to
pay of € 80,000 per QALY, PET-CT-based follow-up and
conventional follow-up have a similar probability of being
cost-effective of approximately 48 %. The probability that
CT is cost-effective is only 5 %. This implies that, although
it is uncertain which diagnostic test is most cost-effective, it
is quite certain that it is not CT.
Table 1 Schematic example of
model input parameters Model Parameter Mean SE/SD/range Distribution Source
Probabilities p
p Progressive Disease 0.85 fixed *
Diagnostics
PET-CT
p imaging test true positive (Sensitivity) * * beta *
p imaging test true negative (Specificity) * * beta *
CT
p imaging test true positive (Sensitivity) * * beta *
p imaging test true negative (Specificity) * * beta *
X-Ray
p imaging test true positive (Sensitivity) * * beta *
p imaging test true negative (Specificity) * * beta *
Costs c (€)
Diagnostics
c PET-CTwhole body 1.364 € fixed [35],*
c CT chest 204 € fixed [35],*
c X-Ray chest 39 € fixed [35],*
Treatment
c * * * * *
Utilities (u)
u No disease 0.68 0.1 beta [1],*
u Progression, detected * * beta [1],*
u Progression, undetected * * beta [1],*
u Dead 0.00 * fixed [1],*
Fig. 4 Cost-effectiveness graph. QALY: Quality adjusted live years.
ICER: Incremental cost-effectiveness ratio
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Transferability and validation
When developing the model, it is important to consider the
decision maker, and the jurisdiction by which the decision is
made. The value of input parameters may well differ between
countries, and the chosen estimates should be relevant for the
given society. This implies, however, that results of decision-
analytic models are not directly transferable to other countries
[40]. A decision model that has been developed for one coun-
try might need adaptation to support decision-making in an-
other. While direct effects such as test accuracy may be gen-
eralizable to other settings, this may not be the case for health
outcomes, resource use, and in particular, costs [41]. For ex-
ample, costs are known to be proportionally lower in Europe
than in the United States (U.S.) [14]. This does not necessarily
imply that the conclusions of a decision model are not gener-
alizable from Europe to the U.S. or vice versa, because the
incremental costs and effects may not differ. In our example,
test accuracy and health outcomes will not differ much be-
tween different countries and are easily transferrable. Costs
though, both direct and indirect, may show considerable var-
iations between countries. It is, therefore, very important that
input parameters of a model are transparently described. This
allows others to explore whether the inputs are relevant for
their country or decision problem, and if not, how this may
affect the results. It is then possible to recalculate results based
on modified cost parameters. Deterministic sensitivity analy-
ses, where parameters are changed in order to explore the
impact of the parameter on the results, may also be helpful
to address the issue of transferability of the results to other
settings [41].
A transparent description of all inputs and choices is also
important for reasons of validity. In every decision-analytic
model, the validity of the results is dependent on the validity
of the inputs. A model can be validated by means of face
validity (evaluation of model structure, data sources,
assumptions and results by experts), verification or internal
validity (check accuracy of coding), cross validity (compari-
son of results with other models analyzing the same problem),
external validity (comparing model results with real-world
results), and predictive validity (comparing model results with
prospectively observed events) [42].
Conclusion
This article illustrates the possibilities and challenges of CEA
in DI. In order to provide DI professionals with an introduc-
tion to the tools necessary to perform and interpret CEA, we
describe a comprehensive framework of direct and indirect
effects that should be considered, suitable for all imaging mo-
dalities. The framework is supported by a six-step methodol-
ogy for complete and uniform CEA studies in DI.
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Fig. 5 Schematic example of
cost-effectiveness acceptability
curves (CEACs). The probability
of cost-effectiveness of three
investigated imaging tests is
plotted against the willingness to
pay for a quality adjusted life year
(QALY) [6]
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